These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

If you continue to have this issue please contact [email protected]. Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinson’s disease. A phase 3 randomized ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

Study finds that a significant proportion of adults prescribed GLP-1 RAs for weight management discontinue treatment within a ...

The researchers found that 98 unique websites sold any GLP-1 RA during the study period; the analysis included 79 of these websites that sold compounded GLP-1 RAs or a prescription for compounded ...

Analyses were conducted separately for patients with and without type 2 diabetes. The study found that most adults with overweight or obesity discontinued GLP-1 RA therapy within a year, with ...